RBC Capital Markets announced on 16 July 2026 that it downgraded its rating on ResMed Inc. to Sector Perform from Outperform. The Canadian investment bank cited a more challenging outlook for the medical device maker heading into its fiscal year 2027. The analyst team maintained a price target of $240, representing an approximate 20% discount to its prior Outperform-rated fair value assessment. ResMed shares closed at $198.50 on the session prior to the downgrade.
Context — why this matters now
The financial landscape for sleep therapy device makers has shifted markedly since the resolution of the Philips Respironics recall saga in late 2025. That multi-year event created an unprecedented market share windfall for competitors like ResMed. The last comparable major analyst action on ResMed occurred in November 2025, when Goldman Sachs initiated coverage with a Buy rating and a $275 target, citing the durable tailwind from the recall. The current macro backdrop features a 10-year Treasury yield at 4.2% and the S&P 500 Healthcare Sector index trading near flat for the year. The catalyst for RBC's reassessment is the looming normalization of competitive dynamics, as Philips completes its remediation program and begins a concerted effort to reclaim lost market share in the core continuous positive airway pressure (CPAP) segment.
RBC's analysis pivots on the transition from a supply-constrained, duopoly-benefiting environment to one defined by renewed commercial intensity. The firm's models now forecast a deceleration in ResMed's top-line growth from the mid-teens percentage range observed during the recall period to high-single digits by FY27. This shift triggers a reassessment of the premium valuation multiple the stock has commanded. The downgrade reflects a judgment that the easy gains from market dislocation have been realized, and future performance will be tied to execution in a more normalized, competitive market.
Data — what the numbers show
ResMed's stock performance illustrates the changing sentiment. The stock is down 12% year-to-date, underperforming the iShares U.S. Medical Devices ETF (IHI), which is down 4% over the same period. ResMed's current forward price-to-earnings ratio stands at 24.5x, a premium to the medical device sector average of 21x. The company reported Q3 FY26 revenue of $1.18 billion, a 9% year-over-year increase, marking a sequential slowdown from the 15% growth reported in Q2.
| Metric | Pre-Downgrade View (Outperform) | Post-Downgrade View (Sector Perform) |
|---|
| FY27 Revenue Growth Implied | ~11-13% | ~8-9% |
| FY27 EPS Estimate | $9.40 | $9.10 |
| Justified P/E Multiple | ~28x | ~24x |
ResMed's market capitalization is approximately $29 billion. The company holds about 45% global market share in sleep therapy devices, a figure that peaked following Philips' exit. Gross margins have remained strong at 56.5%, but operating margin expansion is expected to face pressure from increased sales and marketing expenditures.
Analysis — what it means for markets / sectors / tickers
The downgrade signals a sector-wide recalibration. Direct competitors stand to see relative benefit. Inspire Medical Systems, a maker of implantable sleep apnea devices, could see increased investor interest as an alternative play on obstructive sleep apnea treatment unaffected by the CPAP competitive fray. Its stock, trading at a significant revenue multiple premium, may attract flows from investors rotating out of ResMed. Conversely, suppliers to the sleep therapy industry, like semiconductor firms providing sensors for devices, face a reduced growth outlook from their largest customers.
A key limitation to RBC's thesis is the potential for slower-than-expected recovery by Philips. Execution missteps or regulatory hurdles in its return to the market could prolong ResMed's advantageous position. ResMed's growing software-as-a-service revenue stream, primarily from its AirView patient management platform, provides a more durable, high-margin revenue base that may offset some device-side pressures. Positioning data shows institutional ownership of RMD remains high at over 80%, but the downgrade may trigger outflows from funds mandated to hold only Outperform-rated stocks, creating near-term technical selling pressure.
Outlook — what to watch next
The primary catalyst is ResMed's Q4 FY26 earnings report, scheduled for late July 2026. Guidance for FY27 will be the critical data point, with any forecast below 10% revenue growth likely validating RBC's concerns. Investors should monitor the next FDA clearance update for Philips' next-generation CPAP devices, expected in Q3 2026. A smooth approval would confirm the competitive timeline.
Key levels to watch for ResMed's stock include technical support near $190, its 200-day moving average, and resistance at the $215 level, which represents the pre-downgrade consolidation zone. If the 10-year Treasury yield rises above 4.5%, it would apply further valuation pressure on all growth-oriented healthcare stocks, including RMD. Monitoring quarterly market share data from independent analysts like IQVIA will provide real-time evidence of competitive shifts.
Frequently Asked Questions
What does the ResMed downgrade mean for dividend investors?
ResMed has a history of consistent dividend payments, with a current yield around 1.1%. The RBC downgrade is based on growth and valuation concerns, not dividend safety. The company's strong cash flow generation from its installed base supports the dividend. However, dividend growth rates may moderate if earnings growth slows as projected, potentially making the stock less attractive to income-focused investors seeking high dividend growth.
How does this downgrade compare to analyst actions on Philips?
Analyst sentiment on Philips has been improving as it exits the recall period. In contrast to ResMed's downgrade, Philips has received several upgrades to Buy or equivalent ratings over the past six months, with price targets reflecting an expected recovery. This creates a direct divergence in analyst outlooks for the two duopoly players, underscoring the mean-reversion trade at play: money flows from the beneficiary of a crisis (ResMed) back to the recovering entity (Philips).
What is the long-term market size for sleep apnea devices?
The global sleep apnea devices market is projected to reach approximately $12 billion by 2028, growing at a compound annual growth rate of 7.5% from 2023, according to Grand View Research. This growth is driven by rising obesity rates, increased diagnostic awareness, and aging populations. The competitive battle between ResMed and Philips is for share within this expanding, but no longer hyper-growth, total addressable market.
Bottom Line
RBC's downgrade marks a pivotal shift in ResMed's investment narrative from cyclical beneficiary to a company facing normalized growth and valuation pressures.
